1.Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities.
Seo Yun KIM ; Sang Min LEE ; Jae Joon YIM ; Chul Gyu YOO ; Young Whan KIM ; Sung Koo HAN ; Seok Chul YANG
Yonsei Medical Journal 2013;54(5):1227-1233
PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9+/-3.3 months in the comorbidity group and 9.3+/-3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients.
Age Factors
;
Aged
;
Aged, 80 and over
;
Antitubercular Agents/adverse effects/*therapeutic use
;
Comorbidity
;
Female
;
Humans
;
*Immunocompromised Host
;
Isoniazid/adverse effects/*therapeutic use
;
Male
;
Retrospective Studies
;
Rifampin/adverse effects/*therapeutic use
;
Risk Factors
;
Treatment Outcome
;
Tuberculosis/*drug therapy/epidemiology/immunology
3.A meta-analysis of liver lesions in hepatitis B patients undergoing anti-tuberculosis therapy.
Yixiang ZHENG ; Shujuan MA ; Deming TAN ; Menghou LU
Chinese Journal of Hepatology 2014;22(8):585-589
OBJECTIVETo evaluate the effect of different immune status on the incidence of hepatic lesions in patients with hepatitis B virus (HBV) infection undergoing anti-tuberculosis therapy.
METHODSThe PubMed (1966-2013), Embase (1966-2013), Wanfang (1998-2013), Chinese National Knowledge Infrastructure (CNKI; 1997-2013), and Chinese Biomedical (CBMdisc; 1860-2013) literature databases were searched for case-control studies of hepatic lesions in patients undergoing anti-tuberculosis therapy with or without concomitant HBV infection. The HBV patients were divided into subgroups according to hepatitis B e antigen (HBeAg) positivity or negativity, all members of the control group were HBsAg⁻. The data from all 7 studies included in the meta-analysis were extracted and analysed using RevMan5.2 soft-ware.
RESULTSPatients with HBV infection who were undergoing anti-tuberculosis therapy had a higher risk factor than the control patients (OR =5.81, 95% CI =[4.26, 7.39]). The HBV patients with HBeAg positivity who were undergoing anti-tuberculosis therapy had a high risk factor than the HBV patients with HBeAg negativity (OR =2.56, 95% CI=[1.90, 3.44]).
CONCLUSIONHBV infection is a risk factor for hepatic lesions when undergoing anti-tuberculosis therapy, and HBeAg-positive status may put a patient at higher risk.
Antitubercular Agents ; adverse effects ; therapeutic use ; Hepatitis B ; complications ; pathology ; Hepatitis B e Antigens ; blood ; Humans ; Liver ; drug effects ; pathology ; Tuberculosis ; complications ; drug therapy ; pathology
4.Stevens-Johnson Syndrome and Hypothermia Associated with Anti-tuberculosis Medication in a Patient with Heart Failure.
Sang-Ok JUNG ; Min-Ji CHO ; Dong-Il PARK ; Sun-Young KIM ; Ju-Ock KIM ; Sung-Soo JUNG ; Hee-Sun PARK ; Jeong-Eun LEE ; Jae-Young MOON ; Chae-Uk CHUNG
Chinese Medical Journal 2015;128(20):2837-2838
5.Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China.
Xi Qin HAN ; ; Yu PANG ; ; Yan MA ; ; Yu Hong LIU ; ; Ru GUO ; ; Wei SHU ; ; Xue Rui HUANG ; ; Qi Ping GE ; ; Jian DU ; ; Wei Wei GAO ;
Biomedical and Environmental Sciences 2017;30(2):139-142
We assessed the incidence of adverse drug reactions (ADRs) with anti-TB medications and evaluated the risk factors for developing ADRs in previously treated tuberculosis patients in China. All patients received the first-line anti-TB regimen (2HREZS/6HRE) as recommended by the national guidelines. Clinical and laboratory evaluations were performed once a month. Out of the 354 participants, 262 (74.0%) experienced ADRs such as hyperuricemia (65.0%, 230/354), hepatotoxicity (6.2%, 22/354) and hearing disturbances (4.8%, 17/354). ADRs were significantly associated with diabetes mellitus [OR (95% CI): 15.5 (2.07-115.87)]; however, weight more than 50 kg [OR (95% CI): 0.41 (0.22-0.85)] was a protective factor for occurrence of ADRs. Hyperuricemia is the most common adverse event but, most patients with hyperuricemia showed increased tolerance for high uric acid levels. Low body weight and diabetes mellitus increased the risk of the occurrence of ADRs during anti-TB treatment.
Adolescent
;
Adult
;
Antitubercular Agents
;
adverse effects
;
therapeutic use
;
Diabetes Mellitus
;
Female
;
Humans
;
Male
;
Middle Aged
;
Prevalence
;
Retrospective Studies
;
Risk Factors
;
Tuberculosis, Pulmonary
;
drug therapy
;
epidemiology
;
Young Adult
6.Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels.
Ina JEONG ; Jong Sun PARK ; Young Jae CHO ; Ho Il YOON ; Junghan SONG ; Choon Taek LEE ; Jae Ho LEE
Journal of Korean Medical Science 2015;30(2):167-172
The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity, 12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Alanine Transaminase/blood
;
Antitubercular Agents/adverse effects/*blood/therapeutic use
;
Aspartate Aminotransferases/blood
;
Drug-Induced Liver Injury/*blood
;
Ethambutol/adverse effects/blood/therapeutic use
;
Female
;
Humans
;
Isoniazid/adverse effects/blood/therapeutic use
;
Liver/*pathology
;
Liver Function Tests
;
Male
;
Middle Aged
;
Pyrazinamide/adverse effects/blood/therapeutic use
;
Retrospective Studies
;
Rifampin/adverse effects/blood/therapeutic use
;
Tuberculosis, Pulmonary/drug therapy
;
Young Adult
7.Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels.
Ina JEONG ; Jong Sun PARK ; Young Jae CHO ; Ho Il YOON ; Junghan SONG ; Choon Taek LEE ; Jae Ho LEE
Journal of Korean Medical Science 2015;30(2):167-172
The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity, 12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Alanine Transaminase/blood
;
Antitubercular Agents/adverse effects/*blood/therapeutic use
;
Aspartate Aminotransferases/blood
;
Drug-Induced Liver Injury/*blood
;
Ethambutol/adverse effects/blood/therapeutic use
;
Female
;
Humans
;
Isoniazid/adverse effects/blood/therapeutic use
;
Liver/*pathology
;
Liver Function Tests
;
Male
;
Middle Aged
;
Pyrazinamide/adverse effects/blood/therapeutic use
;
Retrospective Studies
;
Rifampin/adverse effects/blood/therapeutic use
;
Tuberculosis, Pulmonary/drug therapy
;
Young Adult
8.Scanning laser polarimetry in pulmonary tuberculosis patients on chemotherapy.
Wilson W T TANG ; Jimmy S M LAI ; Clement C Y THAM ; Kam-Keung CHAN ; Kin-Sang CHAN
Annals of the Academy of Medicine, Singapore 2006;35(6):395-399
INTRODUCTIONThe aim of this study was to analyse the thickness of the retinal nerve fibre layer (RNFL) of pulmonary tuberculosis patients on ethambutol and isoniazid.
MATERIALS AND METHODSThis was a prospective cohort study where patients with newly diagnosed pulmonary tuberculosis requiring chemotherapy, including ethambutol and isoniazid, were imaged using scanning laser polarimetry. Their mean baseline RNFL thickness and various scanning laser polarimetry parameters of both eyes were measured 2 weeks after the commencement of chemotherapy. The measurements were repeated at 3 months and 6 months after treatment. The various parameters of the baseline and the follow-up measurements were compared using paired sample t-test with Bonferroni correction.
RESULTSTwenty-four patients (16 males and 8 females; mean age, 51.0 +/- 17.6 years) were recruited. There was no statistically significant difference between the baseline and the follow-up measurements in RNFL thickness and all other scanning laser polarimetry parameters.
CONCLUSIONIn this cohort of subjects, there was no subclinical change in RNFL thickness detected by scanning laser polarimetry in pulmonary tuberculosis patients on chemotherapy, including ethambutol and isoniazid, after 6 months of treatment.
Adult ; Aged ; Aged, 80 and over ; Antitubercular Agents ; adverse effects ; therapeutic use ; Diagnostic Techniques, Ophthalmological ; Ethambutol ; adverse effects ; therapeutic use ; Female ; Humans ; Isoniazid ; adverse effects ; therapeutic use ; Lasers ; Male ; Middle Aged ; Prospective Studies ; Retinal Diseases ; chemically induced ; diagnosis ; Tuberculosis, Pulmonary ; drug therapy
9.Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes.
Jinwoo LEE ; Chang Hoon LEE ; Deog Kyeom KIM ; Ho Il YOON ; Jae Yeol KIM ; Sang Min LEE ; Seok Chul YANG ; Jae Ho LEE ; Chul Gyu YOO ; Choon Taek LEE ; Hee Soon CHUNG ; Young Whan KIM ; Sung Koo HAN ; Jae Joon YIM
The Korean Journal of Internal Medicine 2011;26(2):153-159
BACKGROUND/AIMS: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). METHODS: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). RESULTS: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65). CONCLUSIONS: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.
Adult
;
Antitubercular Agents/adverse effects/*therapeutic use
;
Aza Compounds/adverse effects/*therapeutic use
;
Case-Control Studies
;
Chi-Square Distribution
;
*Drug Resistance, Multiple, Bacterial
;
Drug Therapy, Combination
;
Extensively Drug-Resistant Tuberculosis/*drug therapy/microbiology/mortality
;
Female
;
Humans
;
Logistic Models
;
Male
;
Middle Aged
;
Mycobacterium tuberculosis/*drug effects/pathogenicity
;
Odds Ratio
;
Ofloxacin/adverse effects/*therapeutic use
;
Quinolines/adverse effects/*therapeutic use
;
Recurrence
;
Remission Induction
;
Republic of Korea
;
Retrospective Studies
;
Risk Assessment
;
Risk Factors
;
Time Factors
;
Treatment Outcome
;
Tuberculosis, Multidrug-Resistant/*drug therapy/microbiology/mortality
10.Protective effect of silibinin on liver injury induced by antituberculosis drugs.
Jin LI ; Wen-feng LIN ; Yan-yu PAN ; Xiao-yan ZHU
Chinese Journal of Hepatology 2010;18(5):385-386
Adolescent
;
Adult
;
Aged
;
Antitubercular Agents
;
adverse effects
;
Child
;
Female
;
Hepatic Insufficiency
;
chemically induced
;
prevention & control
;
Humans
;
Liver
;
drug effects
;
physiopathology
;
Male
;
Middle Aged
;
Silymarin
;
therapeutic use
;
Tuberculosis, Pulmonary
;
drug therapy
;
physiopathology
;
Young Adult